Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.

AIMS To identify the human cytochrome P450 enzyme(s) involved in the in vitro metabolism of rosiglitazone, a potential oral antidiabetic agent for the treatment of type 2 diabetes-mellitus. Method The specific P450 enzymes involved in the metabolism of rosiglitazone were determined by a combination of three approaches; multiple regression analysis of the rates of metabolism of rosiglitazone in human liver microsomes against selective P450 substrates, the effect of selective chemical inhibitors on rosiglitazone metabolism and the capability of expressed P450 enzymes to mediate the major metabolic routes of rosiglitazone metabolism. Result The major products of metabolism following incubation of rosiglitazone with human liver microsomes were para-hydroxy and N-desmethyl rosiglitazone. The rate of formation varied over 38-fold in the 47 human livers investigated and correlated with paclitaxel 6alpha-hydroxylation (P<0.001). Formation of these metabolites was inhibited significantly (>50%) by 13-cis retinoic acid, a CYP2C8 inhibitor, but not by furafylline, quinidine or ketoconazole. In addition, both metabolites were produced by microsomes derived from a cell line transfected with human CYP2C8 cDNA. There was some evidence for CYP2C9 playing a minor role in the metabolism of rosiglitazone. Sulphaphenazole caused limited inhibition (<30%) of both pathways in human liver microsomes and microsomes from cells transfected with CYP2C9 cDNA were able to mediate the metabolism of rosiglitazone, in particular the N-demethylation pathway, albeit at a much slower rate than CYP2C8. Rosiglitazone caused moderate inhibition of paclitaxel 6alpha-hydroxylase activity (CYP2C8; IC50=18 microm ), weak inhibition of tolbutamide hydroxylase activity (CYP2C9; IC50=50 microm ), but caused no marked inhibition of the other cytochrome P450 activities investigated (CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A and 4A). Conclusion CYP2C8 is primarily responsible for the hydroxylation and N-demethylation of rosiglitazone in human liver; with minor contributions from CYP2C9.

[1]  D. Back,et al.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. , 1988, British journal of clinical pharmacology.

[2]  G. Tucker,et al.  Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. , 1988, The Journal of pharmacology and experimental therapeutics.

[3]  S. Emiliani,et al.  Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. , 1991, European journal of biochemistry.

[4]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[5]  M. Relling,et al.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.

[6]  C. Lieber,et al.  Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. , 1989, Archives of biochemistry and biophysics.

[7]  F. Gonzalez,et al.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.

[8]  A. Guillouzo,et al.  Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[9]  M. Relling,et al.  Variability in human cytochrome P450 paclitaxel metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[10]  J. Miners,et al.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.

[11]  P. Maurel,et al.  Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  S. Wrighton,et al.  Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.

[13]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[14]  B. Monsarrat,et al.  Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. , 1994, Cancer research.

[15]  K. Korzekwa,et al.  Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. , 1994, Cancer research.

[16]  J. Bloomer,et al.  Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. , 1994, Chemical research in toxicology.

[17]  R. Chenery,et al.  Determination of P4501A2 activity in human liver microsomes using [3-14C-methyl]caffeine. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  H. Dirven,et al.  Lauric acid hydroxylase activity and cytochrome P450 IV family proteins in human liver microsomes. , 1991, Biochemical pharmacology.

[19]  S. Clarke,et al.  Characterization of the inhibition of P4501A2 by furafylline. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  G. C. Bolton,et al.  The fate of a thiazolidinedione antidiabetic agent in rat and dog. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  U. Meyer,et al.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. , 1988, Biochemistry.

[22]  A. Boobis,et al.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.

[23]  C. Crespi.  Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .

[24]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[25]  G. Smith,et al.  Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  J. Miners,et al.  Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. , 1988, Biochemical pharmacology.

[27]  D. Greenblatt,et al.  Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. , 1998, Journal of pharmaceutical sciences.

[28]  T. Kronbach,et al.  Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. , 1985, Analytical biochemistry.